British drugmaker Shire PLC said clinical trial data showed its ADHD patch Daytrana reduced symptoms and was safe in children ages 13 to 17. Daytrana currently is approved for children ages 6 to 12.
Published in Brief:
|Senior Director, Biostatistics||
|Associate - Food and Drug||
Keller and Heckman LLP
|Senior Paralegal - Research & Development, and Medical||